Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poliovirus type 1 antigen (inactivated) is a purified, inactivated form of the poliovirus type 1, used as a component of inactivated polio vaccines (IPV). It stimulates the immune system to produce neutralizing antibodies, preventing viral spread and protecting against paralytic disease. The antigen is produced by propagating the virus in continuous lines of monkey kidney cells and then inactivating it with formaldehyde. It is administered via intramuscular or intradermal injection and has a highly favorable safety record.
Stimulates the immune system to produce neutralizing antibodies specific for poliovirus type 1, preventing viral spread to the central nervous system and protecting against paralytic disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus Type 1 Antigen (Inactivated).